Many recent vaping injuries have been linked to e-cigarette use of THC oils or other cannabis oil products, raising new concerns about patients with cancer who use the devices for medical marijuana.
This review discusses nutritional interventions and management of nutritional status in elderly patients with cancer.
A phase 3 trial looking at nivolumab and ipilimumab in advanced melanoma has reported increased survival with the combination, but notable toxicities.
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
Ultrahypofractionated SBRT can deliver radiotherapeutic doses in 2 weeks or fewer without increasing toxicity risk, according to findings from PACE-B.
FDA documents have been a trove of information for researchers, leading to new insights about the safety and efficacy of a drug. An FDA proposal could end that.
Evidence is emerging about the safety and efficacy of CAR-T therapy and CRISPR-based editing techniques in cancer patients with HIV.
Final results of a landmark trial confirm the efficacy of ibrutinib for CLL and SLL—and while cardiovascular issues remain a concern, the benefits appear to outweigh the risks.
A small study on patients with metastatic melanoma who were treated with autologous vaccines in a phase 2 clinical trial suggests that soluble PD-1 may have potential as a prognostic biomarker.
In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
If validated, a patient-specific ctDNA assay for residual disease after neoadjuvant therapy could bring an end to the surgery-for-all approach in breast cancer.
Researchers summarized the novel techniques and models currently being developed to improve prognostication in diffuse large B-cell lymphoma.
It is hypothesized that BAFF-R could prevent the emergence of CD19-based antigen loss.
Since its inception, the Open Payments act does not appear to have prompted physicians to accept fewer payments from industry overall.